Locations:
Elevated levels of the gut microbial metabolite predict prevalence and adverse outcomes in community-based study
Phase 1 trial shows up to 97% decrease through 48 weeks with good tolerability
Post hoc ALPACA analysis boosts biological rationale for ongoing outcomes trial of lepodisiran
Durability findings propel potential one-time treatment approach to phase 1b testing
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Post hoc analysis of CLEAR Outcomes trial bolsters its case as a statin alternative
How to talk about lifetime risk, treatment goals, Lp(a) testing, statin skepticism and more
Post hoc analysis of SURPASS-CVOT trial has implications for future cardiovascular outcome trials
First-in-human phase 1 trial induced loss of function in gene that codes for ANGPTL3
Phase 3 TANDEM study may help pave way to first approval of a CETP inhibitor
Yet 21.4% of tested individuals had Lp(a) elevation
Advertisement
Advertisement
Search